CD19 and systemic lupus erythematosus: Moreover, a clinical trial evaluated allogeneic anti-CD19 CAR-T cells (TyU19), engineered using CRISPR/Cas9 to disrupt TRAC, HLA-A, HLA-B, CIITA, and PD-1 in patients with refractory SLE.